← All trials
NCT04733157
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Dec 31, 2021
- First posted
- Feb 1, 2021
- Last posted
- Apr 14, 2021
- Enrollment
- 1162
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ZimbabweLead sponsor
- University of ZimbabweReponsible party - principal investigator
- University of ZimbabweOverall official - principal investigator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.